Table 1 The distribution of gender, cancer diagnosis, and the prevalence of HPV-16 based on age groups
Age group | Total | P value | |||
|---|---|---|---|---|---|
1–30 | 31–60 | 61–90 | |||
Gender | |||||
Female | 0 (0.0%) | 54 (77.1%) | 16 (22.9%) | 70 (46.7%) | 0.010 |
Male | 6 (7.5%) | 66 (82.5%) | 8 (10.0%) | 80 (53.3%) | |
Cancer diagnosis | |||||
Esophageal SCC | 0 (0.0%) | 32 (80.0%) | 8 (20.0%) | 40 (26.7%) | 0.004 |
Nasopharyngeal carcinoma | 0 (0.0%) | 22 (73.3%) | 8 (26.7%) | 30 (20.0%) | |
Tongue | 2 (11.1%) | 16 (88.9%) | 0 (0.0%) | 18 (12.0%) | |
Conjunctiva SCC | 0 (0.0%) | 16 (88.9%) | 2 (11.1%) | 18 (12.0%) | |
Mucoepidermoid carcinoma | 0 (0.0%) | 6 (100%) | 0 (0.0%) | 6 (4.0%) | |
Adenoid cystic carcinoma | 0 (0.0%) | 6 (100%) | 0 (0.0%) | 6 (4.0%) | |
Myoepithelial carcinoma | 2 (33.3%) | 2 (33.3%) | 2 (33.3%) | 6 (4.0%) | |
Lips SCC | 0 (0.0%) | 6 (75.0%) | 2 (25.0%) | 8 (5.3%) | |
Larynx | 2 (16.7%) | 8 (66.7%) | 2 (16.7%) | 12 (8.0%) | |
Oropharyngeal carcinoma | 0 (0.0%) | 6 (100%) | 0 (0.0%) | 6 (4.0%) | |
HPV-16 | |||||
Negative | 2 (1.6%) | 104 (83.9%) | 18 (14.5%) | 124 (82.7%) | 0.002 |
Positive | 4 (15.4%) | 16 (61.5%) | 6 (23.1%) | 26 (17.3%) | |
Total | 6 (4.0%) | 120 (80.0%) | 24 (16.0%) | 150 (100%) | |